Abstract:Background. Hepatocellular carcinoma (HCC) is one of the deadliest tumors. The majority of HCC is detected in the late stage, and the clinical results for HCC patients are poor. There is an urgent need to discover early diagnostic biomarkers and potential therapeutic targets for HCC.Methods. The GSE87630 and GSE112790 datasets from the Gene Expression Omnibus (GEO) database were downloaded to analyze the differentially expressed genes (DEGs) between HCC and normal tissues. R packages were used for Kyoto Encyclopedia of Genes and Genomes (KEGG) and Gene Ontology (GO) enrichment analyses of the DEGs. A Search Tool for Retrieval of Interacting Genes (STRING) database was used to develop a protein-protein interaction (PPI) network, and also cytoHubba, Molecular Complex Detection (MCODE), EMBL-EBI, CCLE, Gene Expression Profiling Interactive Analysis (GEPIA), and Oncomine analyses were performed to identify hub genes. Gene expression was verified with a third GEO dataset, GSE25097. The Cancer Genome Atlas (TCGA) database was used to explore the correlations between the hub genes and clinical indexes of HCC patients. The functions of the hub genes were enriched by gene set enrichment analysis (GSEA), and the biological significance of the hub genes was explored by real-time polymerase chain reaction (qRT-PCR), western blot, immunofluorescence, CCK-8, colony formation, Transwell and flow cytometry assays with loss-of-function experiments in vitro.Results. Centromere protein N (CENPN) was screened as a hub gene affecting HCC tumorigenesis. Evaluation by Cox regression showed that a high level of CENPN expression was an independent danger variable for poor prognosis of HCC. GSEA showed that high CENPN expression was linked to the following pathways: liver cancer subclass proliferation, cell cycle, p53 signaling pathway, Rb1 pathway, positive regulation of cell cycle G1/S phase transition, and DNA damage response signal transduction by p53 class moderators. Further cell experiments showed that knocking down CENPN expression decreased the proliferation and colony-forming abilities of HepG2 and Huh7 cells as well as Ki67 expression in these cell lines. The cell cycle was arrested in G1 phase, which is consistent with previous experiments on CENPN downregulation., but neither migration nor invasion were significantly affected. Western blot results revealed that the expression of p53, p27, p21, CDK4, cyclin D1, CDK2, cyclin E, pRb, E2F1 and c-myc decreased after CENPN knockdown, but there was no significant change in total Rb levels. In addition, CENPN-knockdown cells subjected to irradiation showed significantly enhanced of gamma-H2AX expression and reduced colony formation.Conclusion. CENPN functions as an oncogene in HCC and may be a therapeutic target and promising prognostic marker for HCC.

A pan-cancer landscape of centromere proteins in tumorigenesis and anticancer drug sensitivity

Immune Infiltration Related CENPI Associates with the Malignant Features and Drug Resistance of Lung Adenocarcinoma.

Comprehensive Pan-Cancer Analysis Identifies Centromere-Associated Protein E As a Novel Prognostic and Immunological Biomarker in Human Tumors.

Centromere Protein F is Identified As a Novel Therapeutic Target by Genomics Profile and Contributing to the Progression of Pancreatic Cancer.

Single-Cell and Bulk RNA Sequencing Analysis Reveals CENPA As a Potential Biomarker and Therapeutic Target in Cancers

Integrated Pan-Cancer Analysis of Centromere Protein F and Experimental Verification of Its Role and Clinical Significance in Cholangiocarcinoma.

Significance of centromere protein genes and their associated immune and metabolic differences in the prediction of prognosis and treatment outcome in breast cancer

Pan-Cancer and Single-Cell Analysis Reveals CENPL as a Cancer Prognosis and Immune Infiltration-Related Biomarker

Pan-Cancer Analysis Reveals CENPI as a Potential Biomarker and Therapeutic Target in Adrenocortical Carcinoma

CENPN Acts as a Novel Biomarker that Correlates With the Malignant Phenotypes of Glioma Cells

Integrative analysis of the expression and prognosis for CENPs in ovarian cancer

High expression of centromere protein A and its molecular mechanism and clinical significance in prostate cancer: A study based on data mining and immunohistochemistry

Bioinformatics-based immunoassay of centromere protein L in pan-cancer

CENPA Acts As a Prognostic Factor That Relates to Immune Infiltrates in Gliomas

Overexpression of CENPF correlates with poor prognosis and tumor bone metastasis in breast cancer

Centromere Protein N May Be A Novel Malignant Prognostic Biomarker For Hepatocellular Carcinoma

Highly expressed CENPL is correlated with breast cancer cell proliferation and immune infiltration

Centromere protein F promotes progression of hepatocellular carcinoma through ERK and cell cycle-associated pathways

CENPF/CDK1 signaling pathway enhances the progression of adrenocortical carcinoma by regulating the G2/M-phase cell cycle

Overexpression of Centromere Protein H is Significantly Associated with Breast Cancer Progression and Overall Patient Survival

Upregulation of Centromere Proteins As Potential Biomarkers for Esophageal Squamous Cell Carcinoma Diagnosis and Prognosis